Intralesional injection of BCG using the fibreoptic bronchoscope in the treatment of bronchogenic carcinoma.
Current evidence suggests that the most effective administration of BCG immunotherapy is by the intralesional route. The new technique and complications of BCG intralesional injection of bronchogenic carcinomas via the fibreoptic bronchoscope is described. Seventeen patients with irresectable bronchogenic carcinoma have been treated with chemotherapy and BCG intralesional immunotherapy. Side-effects observed with intralesional BCG injection are: fever, hypotension and transient mild disturbances of liver function tests, and a single episode of granulomatous hepatitis. Early clinical improvement (nine patients) and radiological regression of the tumour (six patients) have been observed. Cavitation of the tumour has also been observed in three patients. Long term results are not yet available.
D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use; D001999:Bronchoscopy; D002283:Carcinoma, Bronchogenic / Q000628:therapy*; D005336:Fiber Optic Technology; D006801:Humans; D007167:Immunotherapy; D007267:Injections / Q000379:methods; D008175:Lung Neoplasms / Q000628:therapy*; D008875:Middle Aged
D001500:BCG Vaccine